3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
3
Classical hematology
2
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Venous Thrombosis
1
Venous Thromboembolism
1
Vascular Diseases
1
Urogenital Neoplasms
1
Thromboembolism
1
Prostatic Neoplasms
1
Neoplasms
1
Myeloproliferative Disorders
1
Multiple Myeloma
1
Lymphoproliferative Disorders
1
Lymphoma
1
Lymphatic Diseases
1
Lung Neoplasms
1
Leukemia
1
Intestinal Neoplasms
1
Hemostatic Disorders
1
Digestive System Neoplasms
1
Colorectal Neoplasms
1
Breast Neoplasms
1
Interventions
pembrolizumab
19
Magnetic Resonance Spectroscopy
17
Docetaxel
13
Specimen Handling
12
Radiotherapy
11
Surveys and Questionnaires
10
Cyclophosphamide
10
Blood Specimen Collection
9
Radiosurgery
8
Paclitaxel
8
Gemcitabine
8
Drug Therapy
8
sargramostim
7
Trastuzumab
7
Nivolumab
7
Carboplatin
7
Injections
6
Early Intervention, Educational
6
Taxes
5
Psychiatric Rehabilitation
5
Methods
5
Interviews as Topic
5
Educational Status
5
spartalizumab
4
motexafin gadolinium
4
aldesleukin
4
X-Rays
4
Therapeutics
4
Standard of Care
4
Spinal Puncture
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lung Neoplasms
×
Tinzaparin
×
Breast
×
Clear all
NCT03099031
2019-12-16
PREDICARE
LEO Pharma
Completed
420 enrolled